SHERIDAN, WYOMING – May 19, 2025 – Royal Philips has announced the European launch of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter, marking a significant step in transforming structural heart procedures through minimally invasive, real-time imaging technology. Already established in the U.S. market, this cutting-edge device supports more efficient, patient-friendly interventions without requiring general anesthesia — a major development for healthcare providers facing rising demands in structural heart disease care.
Revolutionizing Intracardiac Imaging and Clinical Workflows
VeriSight Pro introduces a miniaturized ultrasound probe at the tip of a steerable catheter, just 3 millimeters in diameter, enabling detailed 2D and 3D imaging directly inside the heart. This innovation allows physicians to perform complex interventions with increased confidence, streamlined workflows, and reduced procedural burden.
“With VeriSight Pro 3D ICE, we now have the ability to see detailed cardiac anatomy from inside the heart in real time,” said Prof. Dr. Jörg Hausleiter, Ludwig-Maximilians-Universität (LMU) Munich, Germany. “This helps streamline our workflows and makes complex procedures more accessible to patients who may not tolerate more invasive imaging approaches.”
Key features of the VeriSight Pro include:
- High-resolution intracardiac 2D and 3D imaging
- Steerable catheter navigation via the femoral vein
- Elimination of general anesthesia requirements
- Real-time anatomical visualization for precise device deployment
- Integration with Philips EPIQ and Azurion platforms for end-to-end workflow optimization
Improving Operational Efficiency and Patient Outcomes
VeriSight Pro addresses growing challenges associated with structural heart disease procedures, such as transcatheter valve repair and left atrial appendage closure, which have traditionally relied on transesophageal echocardiography (TEE). These legacy approaches often demand general anesthesia, prolonged recovery times, and higher resource consumption.
By enabling real-time 3D ICE imaging without general anesthesia, VeriSight Pro helps hospitals:
- Reduce procedure times and staff requirements
- Shorten post-anesthesia care unit (PACU) stays
- Improve patient comfort and recovery
- Enhance overall procedural throughput
“VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience,” said Stacy Beske, Business Leader of Image-Guided Therapy Devices at Philips. “Its availability in Europe is an important milestone in helping more patients benefit from image-guided, minimally invasive heart procedures, while supporting care teams with integrated solutions that adapt to the way they work.”
Integrated Structural Heart Ecosystem and Advanced Imaging Tools
Philips has designed VeriSight Pro to work seamlessly within its broader structural heart care ecosystem. The catheter integrates with Philips EPIQ ultrasound systems and the Azurion image-guided therapy platform, enabling synchronized workflows for procedures like mitral and tricuspid valve repair, atrial septal defect closure, and left atrial appendage occlusion.
Enhanced imaging tools include:
- xPlane technology: Simultaneous visualization of two imaging planes
- iRotate functionality: Digital rotation of imaging views without catheter repositioning
These features allow clinicians to make faster, more informed decisions while minimizing procedural disruptions.
Live Demonstrations and Clinical Engagement at EuroPCR 2025
Philips will spotlight the VeriSight Pro at EuroPCR 2025, taking place May 20–23 in Paris. The company’s presence will feature:
- A physician-led symposium, “Advanced Imaging in Structural Heart Disease Interventions,” with insights from both U.S. and European clinicians
- Hands-on training with VeriSight Pro simulators, in collaboration with Edwards Lifesciences
- An immersive VR-based training experience showcasing real-world clinical protocols
Attendees will gain firsthand experience of 3D ICE’s capabilities and its integration into daily structural heart interventions. Full details are available at www.philips.com/europcr.
Driving Scalable, Patient-Centric Cardiovascular Innovation
As demand for minimally invasive heart procedures continues to rise, Philips’ introduction of the VeriSight Pro 3D ICE catheter in Europe positions the company at the forefront of interventional cardiology innovation. By addressing both clinical and operational pain points, Philips empowers healthcare systems to deliver higher-quality cardiovascular care at scale.
Learn more at www.philips.com/europcr.